ArticleCancer2025

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Mohammed M Milhem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.